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Abstract
Background Atrial fibrillation (AF) is associated with loss of cognition and dementia. Cardiac autonomic dysfunction has 
been linked to cognitive decline. We aimed to investigate if reduced cardiac autonomic function (CAF) is associated with 
cognitive impairment in AF patients.
Methods Patients with paroxysmal, persistent and permanent AF were enrolled from a multicenter cohort study if they had 
AF (“AF group”) or sinus rhythm (“SR group”) on a baseline 5 min ECG recording. Parameters quantifying CAF (heart rate 
variability triangular index (HRVI), mean heart rate (MHR), RMSSD, SDNN, total power and power in the VLF, LF, HF 
ranges) were calculated. We used the Montreal Cognitive Assessment (MoCA) to assess global cognitive function.
Results 1685 AF patients with a mean age of 73 ± 8 years, 29% females, were included. MoCA score was 24.5 ± 3.2 in the AF 
group (N = 710 patients) and 25.4 ± 3.2 in the SR group (N = 975 patients). After adjusting for multiple confounders, lower 
HRVI was associated with lower MoCA scores, both in the SR group [β = 0.049; 95% confidence interval (CI) 0.016–0.081; 
p = 0.003] and in the AF group (β = 0.068; 95% CI 0.020–0.116; p = 0.006). In the AF group, higher MHR was associated 
with a poorer performance in the MoCA (β =  − 0.008; 95% CI − 0.014 to − 0.002; p = 0.014). We found no convincing evi-
dence of association for other CAF parameters with cognition.
Conclusion Our data suggest that impaired CAF is associated with worse cognitive performance in patients with AF. Among 
standard HRV parameters, HRVI might be the most promising ECG index.
Trial registration ClinicalTrials.gov Identifier: NCT02105844.
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Introduction
Cognitive impairment is a global health burden and 
imposes a major challenge to affected individuals, fami-
lies and healthcare systems. Among numerous risk factors, 
atrial fibrillation (AF) is strongly associated with cognitive 
decline [1–5]. Structural brain lesions, including (clini-
cally unrecognized) brain infarcts, white matter lesions 
and microbleeds have been reported to contribute to cogni-
tive dysfunction in AF patients [6, 7].
Cardiac autonomic function (CAF) has been related 
to cognitive performance in sinus rhythm (SR) patients 
[8–13]. CAF can be quantified by means of heart rate 
variability (HRV) derived from Holter ECG but also from 
standard ECG recordings [14]. A cross-sectional analysis 
of a general Irish population revealed that lower quintiles 
of the standard deviation of the normal-to-normal inter-
vals (SDNN), low frequency (LF), and LF:high frequency 
(HF) ratio were associated with lower Montreal Cognitive 
Assessment (MoCA) scores [8]. Another study showed 
that impaired HRV was related to worse performance in 
the Modified Mini-Mental State Examination in elderly 
Mexican Americans [10].
However, previous studies investigating the link between 
CAF and cognition have excluded AF patients due to the 
challenges of quantifying CAF in AF. Therefore, the asso-
ciation between HRV and cognitive performance in patients 
with AF is still unexplored. As AF is related to an increased 
risk of cognitive impairment [1–4], quickly and automati-
cally available parameters that may help to screen for cogni-
tive dysfunction in AF patients are of great clinical interest.
The purpose of this investigation was to examine whether 
HRV is associated with global cognitive performance in 
patients with AF, assessed by the MoCA [15].
Methods
Study population
The present analysis includes patients from the Swiss Atrial 
Fibrillation Cohort (Swiss-AF), an ongoing prospective, 
observational, multicenter cohort study (ClinicalTrials.gov 
Identifier: NCT02105844). In Swiss-AF, 2415 patients with 
documented AF were enrolled across 14 centers in Switzer-
land between 2014 and 2017. The detailed methodology has 
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been described elsewhere [16]. Main inclusion criteria were 
previously documented AF and age ≥ 65 years. Exclusion 
criteria were short secondary, reversible episodes of AF (e.g. 
after cardiac surgery), acute illness within the last 4 weeks 
or if patients were unable to sign the informed consent. The 
study protocol was approved by the local ethic commit-
tees, and written informed consent was obtained from each 
participant.
For this analysis, we had to exclude a total of 730 Swiss-
AF patients: 12 due to missing baseline ECGs, 19 due to 
low quality ECGs, 428 due to rhythms other than SR or AF 
(e.g. paced rhythms, atrial flutter), 260 without brain mag-
netic resonance imaging (bMRI), and 11 due to incomplete 
MoCA. Thus, 1685 Swiss-AF patients remained for this 
analysis, of whom 975 had SR (“SR group”) and 710 had 
AF (“AF group”) on the baseline ECG recording (Fig. 1).
Study variables
Information on individual patient characteristics, medical 
history and current medication was collected using standard-
ized case report forms. Blood pressure was measured three 
times in supine position and the mean was calculated for this 
analysis. AF type was categorized as paroxysmal, persistent 
and permanent according to the guidelines of the European 
Society of Cardiology [17]. Education level was indicated 
using standardized questionnaires, differentiating between 
basic educational level (less than 6 years of school), mid-
dle educational level (7–11 years of school) and advanced 
educational achievement (12 or more years of school). Brain 
MRI was performed at each participating site on a 1.5 or 3 
Tesla scanner, to detect structural brain lesions, including 
large non-cortical or cortical infarcts. These infarcts were 
defined as either hyper-intense lesions on FLAIR > 20 mm in 
diameter on axial sections not involving the cortex or of any 
infarcts involving the cortex. All images were analyzed in a 
core lab by trained MRI technicians and validated by board-
certified radiologists. Brain lesions were evaluated using the 
AMIRA software. The detailed methodology of the bMRI 
protocol has been described previously [7].
Assessment of cardiac autonomic function
16-lead resting ECGs (the standard 12 leads plus 2 addi-
tional precordial leads on the right side and 2 on the back) of 
a duration of 5 min were recorded at baseline in each partici-
pant (CS-200 Excellence and CS-200 Touch, Schiller AG, 
Baar, Switzerland). We saved all ECGs digitally with a sam-
pling frequency of 1 kHz (signal bandwidth 0.04–387 Hz) 
and a resolution of 1 µV/bit on a central server. The fol-
lowing parameters of HRV were calculated according to 
previously published algorithms [18]: heart rate variability 
Fig. 1  Flow chart of patient selection
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triangular index (HRVI), mean heart rate (MHR), root mean 
square of successive differences (RMSSD) and SDNN. We 
performed spectral analysis to calculate frequency domain 
measures of HRV: 5-min total power, power in the very 
low frequency range (VLF, ≤ 0.04 Hz), in the LF range 
(0.04–0.15 Hz) and in the HF range (0.15–0.4 Hz).
Cognitive testing
All study personnel underwent standardized training on how 
to conduct cognitive assessments in the study participants. 
To ensure continuous data quality, experienced staff study 
personnel from the University of Basel centrally trained 
each new investigator at the respective study center. We 
performed cognitive testing using the MoCA score, which 
is a validated global cognitive assessment for screening of 
mild cognitive impairment [15] on the same day as the ECG 
recording. The total test score ranges from 0 to 30, reflect-
ing cognitive capabilities in various domains, such as short-
term memory, visuospatial capacity (e.g. clock-drawing), 
language (e.g. animal naming task) and orientation. Higher 
scores indicate better cognitive performance. Moreover, dif-
ferent areas of executive functions are measured, including 
attention, mental flexibility and working memory. Partici-
pants received one additional point if they had a MoCA 
score < 30 and 12 years or less of formal school education.
Statistical analysis
Baseline characteristics were stratified by the presence of SR 
or AF on baseline ECG recording. Numbers are presented 
as counts (percentage) for categorical variables, means 
(± standard deviation) for normally and medians (interquar-
tile range) for not normally distributed continuous variables. 
Groups are compared using a Chi-square test for categorical 
variables and Student’s t test or Mann–Whitney U test for 
continuous variables.
To investigate the association between CAF and MoCA, 
we performed multivariable adjusted linear regression analy-
ses; we report the β-coefficients and the corresponding 95% 
confidence intervals (CI). The multivariable models were 
adjusted for a pre-defined set of potential confounders (age, 
sex, body mass index (BMI), smoking status (current/past 
vs. never), alcohol consumption [19], presence of large non-
cortical or cortical infarcts, history of hypertension, history 
of diabetes, education (basic, middle, advanced), history of 
oral anticoagulation therapy, intake of beta blockers and/or 
class Ic/III antiarrhythmics). As a sensitivity analysis for 
slight ceiling effects associated with the MoCA, we repeated 
all analyses via a Tobit regression (supplemental material). 
In addition, we built an age-adjusted linear regression model 
to assess the effect of baseline rhythm (SR vs. AF) on cog-
nition (MoCA). Frequency domain measures of HRV were 
log-transformed. All analyses were stratified by baseline 
rhythm. Due to the exploratory nature of this analysis, we 
did not correct p values and CIs for multiple testing. Statisti-
cal analyses were done using SPSS (IBM Corp., Version 22).
Results
Baseline characteristics for the SR group and AF group 
(according to rhythm on baseline ECG) are presented in 
Table 1. Mean age of the study population was 73 ± 8 years 
and 29% were female. Patients in the SR group were 
younger (71 ± 8 years vs 75 ± 8 years), had a lower prev-
alence of co-morbidities, such as hypertension (65% vs 
75%), diabetes (13% vs 19%), prior myocardial infarction 
(11% vs 17%) and heart failure (15% vs 32%). The median 
 CHA2DS2-Vasc-Score was 3.2 in the SR group and 3.8 in the 
AF group. SR group-patients were more often treated with 
non-Vitamin K oral anticoagulants (62% vs 42%) and less 
often with Vitamin K antagonists (25% vs 53%), received 
more often class Ic/III anti-arrhythmics (30% vs 24%) and 
less often beta blockers (65% vs 71%). More patients in the 
SR group had undergone electrical cardioversion (37% vs 
33%) and pulmonary vein isolation (34% vs 6%) compared 
to patients in the AF group. Large non-cortical or corti-
cal infarcts were detected in 16.7% of patients in the SR 
group, with a median volume of 954  mm3. In the AF group, 
large non-cortical or cortical infarcts were found in 29.3% 
(median volume 2679  mm3).
Table 2 shows the results of time and frequency domain 
measures of HRV in the SR group and AF group. All HRV 
measures were higher in the AF group (p < 0.05 for all). 
With regard to cognitive performance, patients in the SR 
group achieved higher MoCA scores (median 26 (IQR 
24–28) vs. median 25 (23–27), p < 0.001, Fig. 2) compared 
to the AF group, which persisted after adjustment for age 
(β-coefficient = 0.438; 95% CI 0.131–0.746; p = 0.005).
Results of the associations between CAF and MoCA 
are presented in Tables 3 and 4. After adjustment for age, 
sex, BMI, smoking status, alcohol consumption, presence 
of large non-cortical or cortical infarcts, history of hyper-
tension, diabetes, education, oral anticoagulation, beta 
blockers and/or class Ic/III antiarrhythmics, lower HRVI 
was associated with lower MoCA scores in the SR group 
(β-coefficient = 0.049; 95% CI 0.016–0.081; p = 0.003). Fur-
thermore, in the AF group, lower HRVI was related to lower 
MoCA scores (β-coefficient = 0.068; 95% CI 0.020–0.116; 
p = 0.006). When additionally adjusted for pre-defined co-
variables (AF duration, intake of non-dihydropyridine cal-
cium channel blockers and digoxin), lower HRVI was still 
associated with lower MoCA scores in the SR and AF group 
(Supplemental Table 1). The results did not change substan-
tially when using a Tobit regression (Supplemental Table 2).
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When patients were categorized into two groups [cogni-
tive impairment (MoCA < 26) vs. no cognitive impairment 
(MoCA ≥ 26 [15])], median HRVI was lower in patients 
with cognitive impairment, both in the SR group [14.3 (IQR 
11.9–18.0) vs 14.7 (IQR 11.7–18.2), Fig. 3 left panel] and in 
the AF group [15.1 (IQR 12.7–18.5) 15.8 (IQR 12.8–19.3), 
Fig. 3 right panel].
We detected no association between MHR and MoCA 
scores in the SR group (β-coefficient =  − 0.003; 95% 
CI − 0.007 to 0.002; p = 0.254). However, in the AF group, 
Table 1  Baseline characteristics of the patients stratified by baseline rhythm
All patients had a diagnosis of atrial fibrillation. Data are means ± SD or counts (percentages)
*p value compares sinus rhythm and atrial fibrillation groups and were obtained from Student’s t tests for continuous variables and chi-square 
tests for categorical variables





Age, years 71 ± 8 75 ± 8  < 0.001
Female sex, N (%) 295 (30) 188 (26) 0.003
Body mass index, kg/m2 27.2 ± 4.9 28.2 ± 4.9  < 0.001
Blood pressure, mm Hg 137 ± 18/78 ± 11 133 ± 19/ 80 ± 13 0.001/0.002
History of hypertension, N (%) 632 (65) 533 (75)  < 0.001
History of diabetes mellitus, N (%) 123 (13) 135 (19)  < 0.001
Active and former smokers, N (%) 545 (56) 400 (56) 0.839
History of electrocardioversion, N (%) 364 (37) 234 (33) 0.064
History of pulmonary vein isolation, N (%) 335 (34) 51 (6)  < 0.001
History of myocardial infarction, N (%) 107 (11) 118 (17) 0.001
History of heart failure, N (%) 142 (15) 226 (32)  < 0.001
History of stroke/TIA, N (%) 164 (17) 171 (24)  < 0.001
CHA2DS2-VASc score, points 3.2 ± 4.3 3.8 ± 1.7  < 0.001
Paroxysmal atrial fibrillation, N (%) 654(67) 110 (15)  < 0.001
Persistent atrial fibrillation, N (%) 321 (33) 210 (30) 0.144
Permanent atrial fibrillation, N (%) – 390 (55) –
Antiarrhythmic therapy (class Ic and III), N (%) 293 (30) 173 (24) 0.010
Beta-blockers, N (%) 631 (65) 501 (71) 0.012
Non vitamin K oral anticoagulants, N (%) 602 (62) 295 (42)  < 0.001
Vitamin K antagonists, N (%) 241 (25) 376 (53)  < 0.001
Table 2  Parameters of heart rate 
variability in patients stratified 
by baseline rhythm
Data are medians and interquartile ranges or means and standard deviations
HF high frequency, HRVI heart rate variability triangular index, LF low frequency, MHR mean heart rate, 
RMSSD square root of the mean squared differences of successive normal-to-normal intervals, SDNN 
standard deviation of the normal-to-normal intervals, VLF very low frequency
*p value compares sinus rhythm and atrial fibrillation groups and was obtained from Mann–Whitney-Test* 
or from Student’s t  testa
b Frequency domain measures of heart rate variability were log-transformed





HRVI 14.4 (11.9–18.05) 15.3 (12.7–18.7)  < 0.001*
MHR 86.4 (45.0–145.1) 101 (77.7–134)  < 0.001*
SDNN 35.7 (20.8–46.9) 53.9 (40.3–74.7)  < 0.001*
RMSSD 85.4(63.4–143.3) 127 (86.8–152)  < 0.001*
5 min total  powerb 3.4 ± 0.8 3.7 ± 0.3  < 0.001a
HFb 2.8 ± 0.7 3.1 ± 0.3  < 0.001a
LFb 3.2 ± 0.8 3.5 ± 0.3  < 0.001a
VLFb 3.1 ± 0.9 3.3 ± 0.6  < 0.001a
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increased MHR was associated with lower MoCA scores 
(β-coefficient =  − 0.008; 95% CI − 0.014 to − 0.002; 
p = 0.014).
Other HRV parameters (RMSSD, SDNN, 5 min total 
power, VLF, LF and HF) were not associated with MoCA, 
neither in the SR nor in the AF group.
Discussion
In this analysis, we studied the association of CAF with cog-
nitive performance in patients with AF. The main findings of 
this study are: first, lower HRVI was associated with lower 
MoCA scores after controlling for covariates, both when 
measured during SR and during AF. Second, higher MHR 
was associated with lower MoCA scores in the AF group. 
Third, RMSSD, SDNN, 5 min total power, VLF, LF and HF 
were not associated with cognitive function.
Our findings are consistent with results from previ-
ous investigations in patients without AF showing that 
impaired HRV is associated with a decline in global cog-
nitive performance [8–13]. HRV analysis is well estab-
lished in SR, because the sinus node can be regarded as 
the “instantaneous writer” of CAF. AF is characterized 
by highly irregular RR intervals; therefore, most studies 
analyzing RR interval series have excluded AF patients. 
However, autonomic factors still may modulate HRV dur-
ing AF on the level of the AV node [20]. In this analysis, 
Fig. 2  Cognitive performance assessed by the MoCA
Table 3  Associations between time domain measures of HRV and the study endpoint (MoCA)
Data are beta-coefficients (β) [95% confidence intervals (CI)]
HRV heart rate variability, HRVI heart rate variability triangular index, MoCA Montreal Cognitive Assessment, MHR mean heart rate, RMSSD 
square root of the mean squared differences of successive normal-to-normal intervals, SDNN standard deviation of the normal-to-normal inter-
vals
*p values were based on linear regression models. Multivariable model was adjusted for age, sex, body mass index, smoking status (current/past 
vs. never), alcohol consumption, presence of large non-cortical or cortical infarcts, history of hypertension, history of diabetes, education (basic, 
middle, advanced), history of oral anticoagulation therapy, intake of beta blockers and/or class Ic/III antiarrhythmics
HRV parameter Sinus rhythm group Atrial fibrillation group
β (95% CI) p value* R2 β (95% CI) p value* R2
HRVI 0.049 (0.016; 0.081) 0.003 0.175 0.068 (0.020; 0.116) 0.006 0.184
MHR  − 0.003 (− 0.007; 0.002) 0.254 0.169  − 0.008 (− 0.014; − 0.002) 0.014 0.183
RMSSD  − 0.008 (− 0.018; 0.001) 0.089 0.170  − 0.006 (− 0.016; 0.003) 0.174 0.178
SDNN 0.001 (− 0.002; 0.003) 0.566 0.168  − 0.001 (− 0.006; 0.004) 0.681 0.176
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we studied CAF parameters in SR and AF in a population 
of patients with AF, who are known to be at risk for cogni-
tive decline and dementia [1–5].
Recently, we were able to demonstrate that impaired 
HRVI, which is a robust measure of overall HRV [18], is 
an independent predictor of mortality in AF patients [14]. 
Here, we showed for the first time that lower HRVI is inde-
pendently associated with a lower cognitive function both 
when assessed during SR and AF. Beta coefficients seem to 
be small on an absolute scale, as each 10 units of HRVI lead 
to a change of 0.5 MoCA points (SR group) and 0.7 MoCA 
points (AF group), respectively. Nevertheless, this equals 
approximately a 5-year (SR group) and 7-year (AF group) 
age difference in cognition, as shown previously [7, 21, 22]. 
Impaired HRVI is also associated with the presence of silent 
brain lesions detected by bMRI in the Swiss-AF cohort [45]. 
Thus, AF patients with low HRVI may be regarded as high-
risk patients.
In addition, we found a higher MHR to be independently 
associated with impaired MoCA scores in the AF group. In 
AF populations, there is some evidence that a higher heart 
rate may be associated with progression of AF, incidence of 
heart failure as well as mortality [23–25]. Similarly, higher 
heart rates predicted unplanned hospitalizations in a post 
hoc analysis of pooled data from the AFFIRM and AF-CHF 
trials [26]. From a pathophysiologic view, the adverse out-
comes associated with elevated heart rates may be due to a 
higher number of isovolumetric contractions, an increase in 
mean arterial pressure and endothelial dysfunction [23, 26]. 
Whether lowering the MHR is sufficient to prevent cognitive 
decline or whether restoring SR by means of rhythm control 
is currently unknown.
Patients who had AF on the single 5 min baseline ECG 
recording indicated lower cognitive functioning (approxi-
mately1 MoCA point) than patients who presented in SR, 
independent of age. This may reflect a progress of cognitive 
Table 4  Associations between 
frequency domain measures of 
HRV and the study endpoint 
(MoCA)
Data are beta-coefficients (β) [95% confidence intervals (CI)]
HF high frequency, HRV heart rate variability, LF low frequency, MoCA Montreal Cognitive Assessment, 
VLF very low frequency
*p values were based on linear regression models. Multivariable model was adjusted for age, sex, body 
mass index, smoking status (current/past vs. never), alcohol consumption, presence of large non-cortical or 
cortical infarcts, history of hypertension, history of diabetes, education (basic, middle, advanced), history 
of oral anticoagulation therapy, intake of betablockers and/or class Ic/III antiarrhythmics
a Frequency domain measures of heart rate variability were log-transformed
HRV parameter Sinus rhythm group Atrial fibrillation group
β (95% CI) p value* R2 β (95% CI) p value* R2
5 min total  powera 0.100 (− 0.132; 0.322) 0.396 0.166  − 0.113 (− 0.847; 0.622) 0.764 0.176
HFa 0.047 (− 0.192; 0.287) 0.699 0.166  − 0.007 (− 0.648; 0.634) 0.982 0.175
LFa 0.009 (− 0.210; 0.228) 0.937 0.166  − 0.187 (− 0.825; 0.451) 0.564 0.176
VLFa 0.036 (− 0.182; 0.254) 0.744 0.169  − 0.288 (− 0.642; 0.066) 0.110 0.182
Fig. 3  Interdependence of heart rate variability triangular index and cognitive impairment in the sinus rhythm group (left panel) and atrial fibril-
lation group (right panel)
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decline in more progressive AF types. Previous studies 
have shown that more progressive disease in AF is associ-
ated with more pronounced cognitive dysfunction [27, 28]. 
Whether this is due to a higher AF burden and possibly a 
higher rate of resulting structural brain lesions [29], impair-
ment of cerebral perfusion due to reduced cardiac output 
[30], or due to a higher burden of co-morbidities warrants 
further investigation.
Numerous factors may contribute to the link between 
impairment of HRV and cognition. For instance, imbalance 
of the cardiac autonomic nervous system is associated with 
poor baroreceptor sensitivity [31, 32]. The baroreceptor 
reflex ensures a continuous and proper blood flow to various 
vital organs, including the brain [33]. Impaired sensitivity of 
the baroreceptor reflex may therefore lead to increased blood 
pressure variability, which is associated with structural brain 
damage and a decline in cognition [34–37]. Structural brain 
lesions, especially right hemispheric or insular stroke, have 
been associated with HRV depression [38]. Furthermore, 
neurodegenerative changes may influence cardiac autonomic 
function via altered autonomic pathways [39]. Finally, cardi-
ovascular risk factors, such as hypertension [40] and diabe-
tes [41], contribute to both cognitive decline and depressed 
HRV [42, 43].
Strengths and limitations
The large sample size of a comprehensively character-
ized and well-treated cohort of patients with AF is a major 
strength of this analysis. Furthermore, over 1600 MRI scans 
with detailed information on structural brain lesions were 
available for this analysis. Therefore, we were able to adjust 
our multivariable model for the presence of large non-corti-
cal or cortical infarcts. Prior analyses of the Swiss-AF cohort 
study have shown that the presence of large non-cortical or 
cortical infarcts are strongly associated with cognition, inde-
pendently of other structural brain lesions, and irrespective 
of a known history of stroke or TIA [7]. Some limitations 
have to be taken into account when interpreting our results. 
First, CAF cannot be assessed during pacing (about 16% 
of the Swiss-AF cohort), therefore these patients had to be 
excluded. Second, results of this analysis are only appli-
cable to short-term ECG recordings (5 min). Therefore, 
the association between CAF and cognition in AF cohorts 
should be investigated using 24 h Holter ECG recordings. 
Third, the results of study should be validated in other AF 
cohorts. Finally, the cross-sectional and observational nature 
of the study does not allow to draw conclusions on cogni-
tive decline over time. In other words, no conclusions on 
causality can be drawn, and confounding effects may still 
be present.
The association of cardiac autonomic dysfunction and 
cognitive impairment is well established in cohorts with 
SR. This is the first study to show that impaired CAF is 
linked to worse cognitive performance in patients with AF. 
Particularly, HRVI may be a promising ECG index, as it 
was independently associated with cognitive dysfunction, 
irrespective if assessed during AF or during SR and despite 
being significantly higher in the AF group compared to the 
SR group. Most recently, the 7th AFNET/EHRA Consensus 
Conference defined cognitive decline as an important AF-
related outcome [44]. AF patients with cognitive impairment 
may benefit from dedicated neuropsychological interven-
tions and intensive treatment of co-morbidities.
Conclusion
The present findings provide a new piece of evidence sug-
gesting a positive association of CAF and cognition. How-
ever, prospective studies with long-term follow-up are 
needed to answer the question whether CAF can identify 
AF patients with risk of future cognitive decline and whether 
loss in cognition can be prevented by treatment of AF by 
means of better rate or rhythm control.
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